Emergency Assessment and Management of Acute Decompensated Heart Failure

Immediate Assessment (First 5–10 min)

The “time‑to‑treatment” principle applies to acute heart failure; therapy should begin as soon as the diagnosis is made. [1][2]
Initial cardiopulmonary evaluation must include respiratory rate, oxygen saturation, blood pressure, heart rate/rhythm, and mental status to gauge severity and determine triage destination. 2
Respiratory distress is defined by any of the following: respiratory rate > 25 breaths/min, SpO₂ < 90 % despite supplemental oxygen, use of accessory muscles, or inability to lie flat. [1][3]
Hemodynamic instability is identified by systolic blood pressure < 90 mmHg, heart rate < 40 bpm or > 130 bpm, and signs of hypoperfusion such as cool extremities, altered mental status, oliguria, or lactate > 2 mmol/L. [4][3]
Congestion assessment should look for jugular venous distension, peripheral edema, and pulmonary rales (rales may be absent in ~20 % of cases). [1][2]

Continuous non‑invasive monitoring (pulse oximetry, blood pressure, respiratory rate, heart rate, and ECG) must be established within minutes of patient contact. [1][2]
A 12‑lead ECG should be obtained immediately to exclude ST‑elevation MI; a completely normal ECG provides >90 % negative predictive value for left‑ventricular systolic dysfunction. [1][2]
Laboratory panel on arrival should include cardiac troponin, BNP or NT‑proBNP, electrolytes, creatinine, BUN, glucose, and a complete blood count. 2
Chest radiography may be normal in up to 20 % of patients with acute decompensation; nevertheless it is performed to rule out alternative causes of dyspnea. [1][2]
When expertise is available, bedside thoracic ultrasound for B‑lines (pulmonary edema) and abdominal ultrasound for inferior‑vena‑cava diameter can aid rapid assessment. [1][2]

Supplemental oxygen is indicated for SpO₂ < 90 %; the target is >90 % while avoiding hyperoxia. [1][2]
Non‑invasive positive‑pressure ventilation (CPAP or BiPAP) should be started immediately in patients with respiratory distress (RR > 25 /min, SpO₂ < 90 %, or increased work of breathing). [1][2]

Patients with systolic blood pressure < 90 mmHg (hypotensive or cardiogenic shock) require immediate transfer to an ICU/CCU for advanced hemodynamic support. [4][3]5

During the first 2 hours, continuous monitoring should include dyspnea severity (visual analog scale), respiratory rate, blood pressure, SpO₂, heart rate/rhythm, urine output, and peripheral perfusion. 1
Clinical status must be reassessed every 15–30 minutes in the initial stabilization phase to evaluate therapeutic response. 1
While on intravenous diuretics, daily weight, strict intake/output recording, and daily electrolytes, creatinine, and BUN measurements are recommended. [4][3]5
A pre‑discharge measurement of natriuretic peptides is useful; a decline in BNP/NT‑proBNP during admission is associated with lower 6‑month cardiovascular mortality and readmission rates. [4][3]5

ICU/CCU admission criteria (any one):
High‑risk features for inpatient admission (predict ~22 % in‑hospital mortality): BUN ≥ 43 mg/dL, systolic blood pressure < 115 mmHg, or creatinine ≥ 2.75 mg/dL. [4][3]5
Invasive hemodynamic monitoring with a pulmonary artery catheter is not recommended in patients without cardiogenic shock, as no benefit has been demonstrated. [4][3]5

Patients are considered medically fit for discharge when they are hemodynamically stable for at least 24 hours, euvolemic (no significant peripheral edema or pulmonary congestion), on evidence‑based oral heart‑failure medications, and have stable renal function for at least 24 hours, with appropriate education and self‑care instructions. [4][3]5
Arrange follow‑up with the primary care physician within 1 week and with a cardiology service within 2 weeks of discharge. [4][3]5
Enrollment in a disease‑management program for chronic heart failure is recommended to improve long‑term outcomes. [4][3]5

The European Society of Cardiology recommends immediate initiation of intravenous loop diuretics (furosemide 20-40 mg IV bolus) combined with vasodilators if systolic blood pressure is >90 mmHg, while establishing continuous monitoring of vital signs, oxygen saturation, and urine output 6, 7, 8
Establish non-invasive monitoring immediately upon diagnosis, including continuous pulse oximetry, blood pressure, respiratory rate, heart rate, and ECG monitoring, with a target oxygen saturation >90% and administration of supplemental oxygen if SpO2 <90% 6, 7, 9
Monitor urine output, symptoms, renal function, and electrolytes (particularly potassium) during diuretic therapy 8, 10

The European Society of Cardiology recommends initiating IV loop diuretics immediately, with a starting dose of furosemide 20-40 mg IV bolus for diuretic-naïve patients or those not on chronic diuretics, and using at least the equivalent of their oral dose IV for patients already on chronic oral diuretics 8, 10
Assess response frequently and increase dose based on urine output and clinical response, with a total furosemide dose remaining <100 mg in the first 6 hours and <240 mg in the first 24 hours 8, 11

Obtain a 12-lead ECG to exclude ST-elevation MI and identify arrhythmias, and laboratory tests including electrolytes, creatinine, glucose, cardiac troponin, and natriuretic peptides (BNP/NT-proBNP) immediately 6, 7, 10, 12
Perform echocardiography after stabilization, especially for de novo heart failure, unless hemodynamic instability is present 6, 7, 12

If inadequate diuresis despite standard dosing, switch to continuous IV furosemide infusion after loading dose, or add thiazide diuretic (hydrochlorothiazide 25 mg PO) or aldosterone antagonist (spironolactone 25-50 mg PO) 8, 11

Avoid inotropic agents unless patient is hypotensive or hypoperfused, as they are not recommended in normotensive patients due to safety concerns 10
Identify and urgently manage precipitants, including acute coronary syndrome, hypertensive emergency, and rapid arrhythmias 13

Continue evidence-based disease-modifying therapies (ACE inhibitors, beta-blockers, aldosterone antagonists) unless hemodynamic instability or contraindications exist, and do not routinely discontinue chronic medications during acute decompensation 10